Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Andrew's Options

<< Previous

Bullboard Posts

Next >>

Comment by lonc17on Nov 19, 2023 12:48pm

179 Views

Post# 35743310

RE:RE:RE:RE:RE:RE:RE:RE:Andrew's Options

Matt Coffey has 175,000 options with a strike price of $1.45 (CDN) and an expiry datae of December 13, 2023.

So at some point in the next few weeks he will likely invest about $250,000 to purchase shares in ONC.

As an executive in the company, he has in the past demonstrated considerable restraint when chossing ONC as an investment. As of today, he currently holds fewer than 100,000 shares in the company!

And it will be a disgrace and insulting to all long term shareholders if he then sells his newly acquired 175,000 shares at any point while moving toward the promised P3 trials.

Let's hope that he works harder and smarter once he has more skin in the game.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China